CA2387652A1 - A method of prophylaxis and treatment - Google Patents

A method of prophylaxis and treatment Download PDF

Info

Publication number
CA2387652A1
CA2387652A1 CA002387652A CA2387652A CA2387652A1 CA 2387652 A1 CA2387652 A1 CA 2387652A1 CA 002387652 A CA002387652 A CA 002387652A CA 2387652 A CA2387652 A CA 2387652A CA 2387652 A1 CA2387652 A1 CA 2387652A1
Authority
CA
Canada
Prior art keywords
cells
antigen
ctl
insulin
proinsulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387652A
Other languages
English (en)
French (fr)
Inventor
Leonard C. Harrison
Arno Hanninen
Nathan R. Martinez
David Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ3627A external-priority patent/AUPQ362799A0/en
Priority claimed from AUPQ4347A external-priority patent/AUPQ434799A0/en
Priority claimed from AUPQ7621A external-priority patent/AUPQ762100A0/en
Application filed by Individual filed Critical Individual
Publication of CA2387652A1 publication Critical patent/CA2387652A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002387652A 1999-10-22 2000-10-20 A method of prophylaxis and treatment Abandoned CA2387652A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPQ3627 1999-10-22
AUPQ3627A AUPQ362799A0 (en) 1999-10-22 1999-10-22 A method of prophylaxis and treatment
AUPQ4347A AUPQ434799A0 (en) 1999-11-26 1999-11-26 A method of propylaxis and treatment - II
AUPQ4347 1999-11-26
AUPQ7621 2000-05-19
AUPQ7621A AUPQ762100A0 (en) 2000-05-19 2000-05-19 A method of prophylaxis and treatment - III
PCT/AU2000/001299 WO2001030378A1 (en) 1999-10-22 2000-10-20 A method of prophylaxis and treatment

Publications (1)

Publication Number Publication Date
CA2387652A1 true CA2387652A1 (en) 2001-05-03

Family

ID=27158188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387652A Abandoned CA2387652A1 (en) 1999-10-22 2000-10-20 A method of prophylaxis and treatment

Country Status (4)

Country Link
EP (1) EP1225912A4 (ja)
JP (1) JP2003512435A (ja)
CA (1) CA2387652A1 (ja)
WO (1) WO2001030378A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006833A1 (en) * 2013-07-19 2015-01-22 St. Vincent's Institute Of Medical Research A method for treating type 1 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530178A (en) * 1991-05-29 1996-06-25 The Ontario Cancer Institute Mutant mouse lacking CD8 surface marker
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
WO1997046573A1 (en) * 1996-06-07 1997-12-11 The University Of Virginia Patent Foundation Method of inhibiting antigen processing, chimeric proteins reflecting this method, and methods of expressing those proteins

Also Published As

Publication number Publication date
WO2001030378A1 (en) 2001-05-03
EP1225912A1 (en) 2002-07-31
JP2003512435A (ja) 2003-04-02
EP1225912A4 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
US8673293B2 (en) Use of modified cells for the treatment of multiple sclerosis
US20240058442A1 (en) Combinations of Modalities for the Treatment of Diabetes
Tseveleki et al. Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis
Fujihashi et al. Mucosal immunity and tolerance in the elderly
EP1292621A1 (en) Compositions and methods for the endocytic presentation of immunosuppressive factors
US20090280132A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
CA2063416C (en) Methods of treating or preventing autoimmune uveoretinitis mammals
US20070253975A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
AU767688B2 (en) A method of prophylaxis and treatment
CA2387652A1 (en) A method of prophylaxis and treatment
WO2007064757A1 (en) Anti-thymocyte globulin to prevent or delay the onset or the progression on type 1 diabetes
US20050025758A1 (en) Method and compositions for treatment of insulin-dependant diabetes mellitus
JP2003512435A5 (ja)
AU2001264813A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
US8940700B2 (en) E-selectin compositions and use thereof for inducing E-selectin tolerance
AU2016275295B2 (en) Multi-peptide composition
WO1998014203A1 (en) A method and compositions for treatment of insulin-dependant diabetes mellitus
HAFLER et al. I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE
WO1998057655A1 (en) A method of enhancing antigen-specific peripheral immune tolerance

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead